Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

PURPOSE: Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. METHODS: Patients received cemiplimab 250 mg (n = 6) or 350 mg (n = 7) e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801352/
https://ncbi.nlm.nih.gov/pubmed/33146741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04161-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires